Erasca, Inc. (ERAS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$47.7M
Cash & Equivalents
$27.4M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$3,878M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04866134 | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | PHASE2 | Active Not Recruiting | 200 |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | PHASE1 | Recruiting | 200 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.